Z. M. Thomas

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

P. Moss, H. McShane, A. Lawrie, 2016, Vaccine.

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants

M. Tameris, M. Hatherill, B. Landry, 2019, JCI insight.

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial

H. McShane, S. Harris, R. Antrobus, 2014, The Lancet. Infectious diseases.

Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine , MVA 85 A

M. Tameris, T. Scriba, W. Hanekom, 2017 .

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults

P. Moss, H. McShane, M. O’Shea, 2019, Vaccine.

Cytomegalovirus infection is a risk factor for TB disease in Infants

M. Tameris, M. Hatherill, B. Landry, 2017, bioRxiv.

Cytomegalovirus infection is a risk factor for TB disease in 1 Infants 2

M. Tameris, M. Hatherill, B. Landry, 2019 .

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial

H. McShane, Joel Meyer, Sharon Sheehan, 2014, The Lancet. Infectious diseases.